Resistance mutation info of target
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T35940 | ||||
Target Name | Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) | Target Info | |||
Gene Name | MAP2K1 | ||||
Species | Homo sapiens | ||||
Uniprot ID | MP2K1_HUMAN | ||||
Sequence | MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKV GELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHE CNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYL REKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHY SVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSY GMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAF IKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV [Homo sapiens] |
||||
Drug Resistance Mutation and Corresponding Drugs | |||||
Mutation Info | Missense: C121S | ||||
Mutation Info | Missense: D67N | ||||
Mutation Info | Missense: E120D | ||||
Mutation Info | Missense: E203K | ||||
Mutation Info | Missense: F129L | ||||
Mutation Info | Missense: F133L | ||||
Mutation Info | Missense: G128D | ||||
Mutation Info | Missense: G128V | ||||
Mutation Info | Missense: H119P | ||||
Mutation Info | Missense: I103N | ||||
Mutation Info | Missense: I111N | ||||
Mutation Info | Missense: I99T | ||||
Mutation Info | Missense: K104N | ||||
Mutation Info | Missense: K57E | ||||
Mutation Info | Missense: K57N | ||||
Mutation Info | Missense: L115P | ||||
Mutation Info | Missense: L215P | ||||
Mutation Info | Missense: P124L | ||||
Mutation Info | Missense: P124S | ||||
Mutation Info | Missense: Q56P | ||||
Mutation Info | Missense: V211D | ||||
Mutation Info | Missense: V60E | ||||
Reference | |||||
Ref 555733 | MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6. doi: 10.1073/pnas.0905833106. Epub 2009 Nov 13. | ||||
Ref 555798 | Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 1;29(22):3085-96. doi: 10.1200/JCO.2010.33.2312. Epub 2011 Mar 7. | ||||
Ref 555849 | ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8. | ||||
Ref 555926 | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res. 2013 Apr 15;19(8):2257-64. doi: 10.1158/1078-0432.CCR-12-3476. Epub 2013 Feb 26. | ||||
Ref 555935 | Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8. | ||||
Ref 555981 | The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.